in vitro News and Research

RSS

Anti-fogging sprays and cloths may contain high levels of PFAS, finds study

The anti-fogging sprays and cloths many people use to prevent condensation on their eyeglasses when wearing a mask or face shield may contain high levels of per- and polyfluorinated alkyl substances (PFAS), a new Duke University-led study finds.

5 Jan 2022

Oral bacteria-based SARS-CoV-2 vaccine platform

In a new study, researchers engineered the bacterial strain, Salmonella, to express differently-sized antigens to serve as vaccine platforms.

5 Jan 2022

Experts cautiously optimistic about risks of Delta-Omicron mutations mix

Researchers evaluate the risk of the P681R, N501Y, and D614G mutations of current interest co-occurring naturally due to convergent evolution.

4 Jan 2022

Efficacy of antibodies induced by natural infection, vaccination, or both against SARS-CoV-2 Omicron and Beta variants

A study has demonstrated that antibodies induced by two-dose COVID-19 vaccination or natural infection exhibit very low neutralizing activity against the omicron variant of SARS-CoV-2.

4 Jan 2022

In vitro effect of several antiviral drugs against various SARS-CoV-2 variants of concern

An independent study confirms that current and prospective antiviral treatments are effective in inhibiting severe infection from SARS-CoV-2.

4 Jan 2022

Siemens Healthineers Announces FDA Emergency Use Authorization for CLINITEST® Rapid COVID-19 Antigen Self-Test

The CLINITEST Rapid COVID-19 Antigen Self-Test has received FDA EUA for unsupervised self-testing for the SARS-CoV-2 virus by individuals age 14 and older (or adult-collected samples from individuals ages 2-13).

From Siemens Healthineers 4 Jan 2022

T-cell responses to SARS-CoV-2 Omicron variant confer protection to vaccinated individuals

Researchers ascertain whether the SARS-CoV-2 Omicron variant evades cellular immunity.

3 Jan 2022

Humanized antibody shows strong neutralization ability against SARS-CoV-2 Delta variant

Researchers combine SARS-CoV-2 spike vaccination with single-cell B-cell receptor sequencing technology to discover neutralizing antibody candidates.

3 Jan 2022

Echinacea, a potent antiviral against SARS-CoV-2

Researchers present available evidence on the activity of Echinacea purpure against coronavirus infections.

3 Jan 2022

P323L mutations in SARS-CoV-2 are highly predictive of the emergence of new variants

In a new study, findings suggest that in some cases, tracking the distribution and frequency of SARS-CoV-2 minor variant genomes at a population level would help in predicting the emergence of a new dominant viral genome sequence.

30 Dec 2021

Intestinal organoids used to explain why bats infected with viruses do not succumb to diseases

Experiments attempting to explain why bats can be infected with many viruses at a time without succumbing to diseases such as COVID-19 - knowledge that could help us to reduce the threat to humans of infectious disease - have struggled until now with the fact that live wild bats make poor research subjects.

30 Dec 2021

An integrated computational methodology for COVID drug prioritization

Researchers recently published a study in the journal Briefings in Bioinformatics wherein they integrated multiple bioinformatics and cheminformatics-based methods to prioritize drugs for the treatment of COVID-19.

29 Dec 2021

COVID mRNA vaccines show diminished neutralization responses against Omicron

Researchers report an overview of antibody neutralization by all currently approved vaccines against the SARS-CoV-2 Omicron, Beta, and Delta VOCs.

29 Dec 2021

Boceprevir-based molecules show high antiviral potency against SARS-CoV-2

In a study posted to the bioRxiv* pre-print server, a team of researchers conducted a structure-activity relationship study of boceprevir-based molecules to find antiviral drug candidates targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protease MPro.

22 Dec 2021

Decline in protection against SARS-CoV-2 Omicron in prior infected and fully vaccinated

In a recent study posted to the medRxiv* preprint server, researchers investigated the distribution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta and Omicron variants among coronavirus disease 2019 (COVID-19) positive individuals who were either naive, fully vaccinated, or had a previous infection to further investigate possible escape from vaccine- or infection-induced immunity by Omicron compared to Delta.

22 Dec 2021

in vitro News and Research

Anti-fogging sprays and cloths may contain high levels of PFAS, finds study

Oral bacteria-based SARS-CoV-2 vaccine platform

Experts cautiously optimistic about risks of Delta-Omicron mutations mix

Efficacy of antibodies induced by natural infection, vaccination, or both against SARS-CoV-2 Omicron and Beta variants

In vitro effect of several antiviral drugs against various SARS-CoV-2 variants of concern

Siemens Healthineers Announces FDA Emergency Use Authorization for CLINITEST® Rapid COVID-19 Antigen Self-Test

T-cell responses to SARS-CoV-2 Omicron variant confer protection to vaccinated individuals

Humanized antibody shows strong neutralization ability against SARS-CoV-2 Delta variant

Echinacea, a potent antiviral against SARS-CoV-2

P323L mutations in SARS-CoV-2 are highly predictive of the emergence of new variants

Intestinal organoids used to explain why bats infected with viruses do not succumb to diseases

An integrated computational methodology for COVID drug prioritization

COVID mRNA vaccines show diminished neutralization responses against Omicron

Boceprevir-based molecules show high antiviral potency against SARS-CoV-2

Decline in protection against SARS-CoV-2 Omicron in prior infected and fully vaccinated

rVSV-based bivalent vaccine against SARS-CoV-2 delta variant and influenza

Omicron evades roughly twice the number of SARS-CoV-2 neutralizing antibodies than Delta

Study suggests nitazoxanide fails to reduce the severity of SARS-CoV-2

Furin cleavage site similarities in SARS-CoV-2 and rodent coronavirus indicate common wildlife host

Diagnostic assays that use the 2019-nCoV-N1 primer-probe are unlikely to be impacted by Omicron variant

eBook: Using iPSCs models for human disease research and drug discovery eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News